Voyager Therapeutics, Inc. (NASDAQ:VYGR) popped in on a high volume green day. Volume on 15-Nov-17 came in at 1 million contracts. The daily trading volume has averaged 0.53 million shares a day in past 3 months. The first sale was made at $12.25 but later the stock became weaker, and closed with a gain of 10.04%. It was last traded at $13.59 apiece.Voyager Therapeutics, Inc. (VYGR): Outperform Candidate With 113.39% Upside Potential
Voyager Therapeutics, Inc. is maintained at an average outperform rating by 10 stock analysts, and there are at least 5.38% of shares outstanding that are currently legally short sold. The shares went down by -40.63% in value last month. Year-to-date it jumped 6.67%. Analysts are turning out to be more optimistic than before, with 9 of analysts who cover Voyager Therapeutics, Inc. (NASDAQ:VYGR) advice adding it to buy candidate list. Wall Street experts also assign a $29 price target on Voyager Therapeutics, Inc., pointing towards a 113.39% rally from current levels. The stock is trading for about -47.71% less than its 52-week high.
Voyager Therapeutics, Inc. (VYGR) remained unsuccessful in beating the consensus-estimated -$0.72 as it actually earned -$0.89 per share in its last reported financial results. Revenue, on the other hand, scored 53.39% growth from the previous quarter, coming up with $1.81 million.VYGR Adds 5.76% In A Week
This company shares (VYGR) so far managed to recover 67.78% since collapsing to its 52-week low. Over a month, it has seen its stock price volatility to stay at 11.07% while shortening the period to a week, volatility was 9.21%. The share price has yet to cross its 20 days moving average, floating at a distance of -27.01% and sits -27.2% lower versus its 50 days moving average. When looking at the past five sessions, the stock returned 5.76% gains and is up by 8.99% compared with its 200-day moving average of $12.64. Also, Voyager Therapeutics, Inc. (VYGR) needs to overturn a -2.58% decrease it experienced over the past twelve months.Vascular Biogenics Ltd. (NASDAQ:VBLT) Consensus Call At 2
As regular trading ended, Vascular Biogenics Ltd. (VBLT) stock brought in a -$1.02 drop to $7.68. The day started at a price of $8.85 but then traded as high as $8.9 before giving part of the gains back. As for this week, analysts appear content to stick with their neutral outlook with the consensus call at 2. Vascular Biogenics Ltd. is given 0 buy-equivalent recommendations, 0 sells and 0 holds. The company shares sank -14.72% from their peak of $9.00 and now has a $201.39 million market value of equity.
VBLT’s mean recommendation on Reuter’s scale presents no change from 2 thirty days ago to 2 now, which indicates a hold consensus from the analyst community. They see Vascular Biogenics Ltd. (VBLT) price hitting a mean target of $13.75 a share, meaning the stock still has potential that could lift the price another 79.04% Also, the recent close suggests the stock is underpriced by 225.52% compared to the most bullish target.Vascular Biogenics Ltd. (VBLT) Returns 58.25% This Year
The company had seen its current volume reaching at 0.72 million shares in the last trade. That compares with the recent volume average of 0.24 million. At the close of regular trading, its last week’s stock price volatility was 7.54% which for the month reaches 9.64%. Vascular Biogenics Ltd. dipped to as low as $7.5 throughout the day and has returned 58.25% in this year. At one point in the past year, the shares traded as low as $3.90 but has recovered 96.79% since then.